Rezolute, Inc. (NASDAQ:RZLT – Get Free Report) has been assigned a consensus rating of “Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $10.43.
A number of equities analysts have weighed in on RZLT shares. BTIG Research began coverage on Rezolute in a research note on Wednesday, July 17th. They set a “buy” rating and a $13.00 price objective on the stock. Craig Hallum started coverage on shares of Rezolute in a research report on Tuesday, June 4th. They set a “buy” rating and a $14.00 price target on the stock. Maxim Group upped their price objective on shares of Rezolute from $8.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, August 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of Rezolute in a research note on Tuesday, August 6th.
Check Out Our Latest Analysis on RZLT
Rezolute Price Performance
Insider Transactions at Rezolute
In related news, CFO Daron Evans acquired 40,000 shares of Rezolute stock in a transaction that occurred on Friday, June 14th. The shares were purchased at an average cost of $4.04 per share, for a total transaction of $161,600.00. Following the acquisition, the chief financial officer now owns 40,000 shares in the company, valued at $161,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last ninety days, insiders acquired 49,566 shares of company stock worth $199,974. 20.80% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Rezolute
Institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new position in shares of Rezolute in the 1st quarter worth approximately $37,000. Jeppson Wealth Management LLC purchased a new stake in Rezolute in the second quarter valued at approximately $45,000. XTX Topco Ltd lifted its stake in Rezolute by 205.8% during the second quarter. XTX Topco Ltd now owns 33,671 shares of the company’s stock worth $145,000 after purchasing an additional 22,660 shares in the last quarter. Acadian Asset Management LLC purchased a new position in shares of Rezolute during the first quarter worth $229,000. Finally, Cubist Systematic Strategies LLC grew its stake in shares of Rezolute by 366.0% in the second quarter. Cubist Systematic Strategies LLC now owns 54,237 shares of the company’s stock valued at $233,000 after buying an additional 42,597 shares in the last quarter. 82.97% of the stock is currently owned by institutional investors and hedge funds.
About Rezolute
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.
See Also
- Five stocks we like better than Rezolute
- How to Invest in Biotech Stocks
- CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- 3 High Short-Interest Stocks Poised for a Rate Cut Squeeze
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- MarketBeat Week in Review – 8/19 – 8/23
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.